ENTRY       D00297                      Drug
NAME        Digitoxin (JAN/USP/INN);
            Crystodigin (TN)
FORMULA     C41H64O13
EXACT_MASS  764.4347
MOL_WEIGHT  764.9391
SOURCE      Digitalis purpurea [TAX:4164]
CLASS       Cardiovascular agent
             DG01703  Cardiotonic
              DG01698  Cardiac glycoside
               DG01697  Digitalis cardiac glycoside
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
REMARK      Same as: C06955
            ATC code: C01AA04
EFFICACY    Cardiotonic
COMMENT     First extracted from the leaves of Digitalis purpurea [TAX:4164]
            Digitalis glycoside
TARGET      ATP1A [HSA:476 477 478 480] [KO:K01539]
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
            Transporter: ABCB1 [HSA:5243]
INTERACTION  
DBLINKS     CAS: 71-63-6
            PubChem: 7847363
            ChEBI: 28544
            PDB-CCD: F9R
            LigandBox: D00297
            NIKKAJI: J8.586C
ATOM        54
            1   C2y C    28.5021  -13.5211
            2   C2x C    29.8578  -13.5206
            3   C7x C    30.2748  -12.2337
            4   O7x O    29.1754  -11.4332
            5   C1x C    28.0840  -12.2347
            6   C1z C    27.3145  -16.8982
            7   C1y C    26.1234  -17.5783
            8   C1z C    27.3262  -15.5389
            9   C1x C    29.6660  -16.8586
            10  O1a O    27.2781  -18.4619
            11  C1y C    24.9629  -16.8807
            12  C1x C    26.1234  -18.9317
            13  C1y C    28.5112  -14.8773
            14  C1x C    26.1538  -14.8529
            15  C1a C    27.2748  -14.0897
            16  C1x C    29.6904  -15.4352
            17  C1z C    23.7019  -17.5725
            18  C1x C    24.9688  -15.5273
            19  C1x C    24.9500  -19.6296
            20  C1y C    23.7590  -18.9317
            21  C1x C    22.5926  -16.8807
            22  C1x C    22.5926  -19.6237
            23  C1x C    21.3959  -17.5725
            24  C1y C    21.3959  -18.9317
            25  O2a O    20.2224  -19.6296
            26  C1y C    18.8456  -18.9260
            27  C1x C    17.6664  -19.6049
            28  O2x O    18.8456  -17.5597
            29  C1y C    16.4814  -18.9260
            30  C1y C    17.6664  -16.8748
            31  C1y C    16.4814  -17.5597
            32  O1a O    15.2960  -19.6049
            33  C1a C    17.6664  -15.4968
            34  O2a O    15.2425  -16.8083
            35  C1y C    13.9427  -17.5597
            36  C1x C    12.7648  -16.8748
            37  O2x O    13.9427  -18.9260
            38  C1y C    11.5796  -17.5597
            39  C1y C    12.7648  -19.6049
            40  C1y C    11.5796  -18.9260
            41  O1a O    10.3944  -16.8619
            42  C1a C    12.7705  -20.9772
            43  O2a O    10.4727  -19.6950
            44  C1y C     9.2093  -18.9260
            45  C1x C     8.0300  -19.6049
            46  O2x O     9.2093  -17.5597
            47  C1y C     6.8582  -18.9260
            48  C1y C     8.0300  -16.8748
            49  C1y C     6.8582  -17.5597
            50  O1a O     5.6820  -19.6049
            51  C1a C     8.0300  -15.4968
            52  O1a O     5.6820  -16.8748
            53  O6a O    31.5753  -11.8719
            54  C1a C    23.7019  -16.1725
BOND        61
            1     5   1 1
            2     1   2 2
            3     2   3 1
            4     6   7 1
            5     6   8 1
            6     6   9 1
            7     6  10 1 #Up
            8     7  11 1
            9     7  12 1
            10    8  13 1
            11    8  14 1
            12    8  15 1 #Up
            13    9  16 1
            14   11  17 1
            15   11  18 1
            16   12  19 1
            17   17  20 1
            18   17  21 1
            19   20  22 1
            20   21  23 1
            21   22  24 1
            22   24  25 1 #Up
            23   26  25 1 #Up
            24   26  27 1
            25   26  28 1
            26   27  29 1
            27   28  30 1
            28   29  31 1
            29   29  32 1 #Down
            30   30  33 1 #Up
            31   31  34 1 #Down
            32   35  34 1 #Down
            33   35  36 1
            34   35  37 1
            35   36  38 1
            36   37  39 1
            37   38  40 1
            38   38  41 1 #Up
            39   39  42 1 #Down
            40   40  43 1 #Up
            41   44  43 1 #Up
            42   44  45 1
            43   44  46 1
            44   45  47 1
            45   46  48 1
            46   47  49 1
            47   47  50 1 #Down
            48   48  51 1 #Up
            49   49  52 1 #Down
            50   13  16 1
            51   14  18 1
            52   19  20 1
            53   23  24 1
            54   30  31 1
            55   39  40 1
            56   48  49 1
            57    3   4 1
            58   13   1 1 #Up
            59    4   5 1
            60    3  53 2
            61   17  54 1 #Up
///
ENTRY       D00749                      Drug
NAME        Leflunomide (JAN/USP/INN);
            Arava (TN)
FORMULA     C12H9F3N2O2
EXACT_MASS  270.0616
MOL_WEIGHT  270.2073
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drugs (DMARDs)
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01643  CYP2C9 inhibitor
REMARK      Same as: C07905
            Therapeutic category: 3999
            ATC code: L04AA13
            Product: D00749<JP/US>
EFFICACY    Antirheumatic, Dihydroorotate dehydrogenase inhibitor
  DISEASE   Active rheumatoid arthritis [DS:H00630]
COMMENT     Antineoplastic (blocks PDGF receptor function, inhibiting the growth and survival of human tumor cells when administered intravenously), Used in the treatment of rheumatoid arthritis when administered orally
TARGET      DHODH [HSA:1723] [KO:K00254]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP2C9 [HSA:1559]
DBLINKS     CAS: 75706-12-6
            PubChem: 7847814
            ChEBI: 6402
            LigandBox: D00749
            NIKKAJI: J227.599F
ATOM        19
            1   C8y C    22.4985  -19.9460
            2   C5a C    23.7261  -19.2621
            3   C8y C    22.4985  -21.3488
            4   C8x C    21.1659  -19.5077
            5   N1b N    24.9360  -19.9577
            6   O5a O    23.7261  -17.8652
            7   O2x O    21.1601  -21.7813
            8   C1a C    23.6268  -22.1788
            9   N5x N    20.3360  -20.6415
            10  C8y C    26.1460  -19.2621
            11  C8x C    26.1460  -17.8592
            12  C8x C    27.3617  -19.9577
            13  C8x C    27.3617  -17.1637
            14  C8x C    28.5657  -19.2621
            15  C8y C    28.5657  -17.8592
            16  C1d C    29.7756  -17.1580
            17  X   F    30.9798  -16.4506
            18  X   F    29.0684  -15.9421
            19  X   F    30.4653  -18.3677
BOND        20
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 1
            5     2   6 2
            6     3   7 1
            7     3   8 1
            8     4   9 2
            9     5  10 1
            10   10  11 2
            11   10  12 1
            12   11  13 1
            13   12  14 2
            14   13  15 2
            15   15  16 1
            16   16  17 1
            17   16  18 1
            18   16  19 1
            19    7   9 1
            20   14  15 1
///
ENTRY       D00963                      Drug
NAME        Exemestane (JAN/USP/INN);
            Aromasin (TN)
FORMULA     C20H24O2
EXACT_MASS  296.1776
MOL_WEIGHT  296.4034
CLASS       Antineoplastic
             DG01596  Aromatase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Same as: C08162
            Therapeutic category: 4291
            ATC code: L02BG06
            Product: D00963<JP/US>
EFFICACY    Antineoplastic, Estrogen biosynthesis inhibitor
  DISEASE   Breast cancer, postmenopausal (ER-positive) [DS:H00031]
COMMENT     Aromatase inhibitor
TARGET      CYP19A1 (ARO) [HSA:1588] [KO:K07434]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     CAS: 107868-30-4
            PubChem: 7848026
            ChEBI: 4953
            PDB-CCD: EXM
            LigandBox: D00963
            NIKKAJI: J367.471A
ATOM        22
            1   C2x C    12.2500  -16.2400
            2   C5x C    12.2500  -17.6400
            3   C2x C    13.4624  -18.3400
            4   C2y C    14.6749  -17.6400
            5   C1z C    14.6749  -16.2400
            6   C2x C    13.4624  -15.5400
            7   C2y C    15.8873  -18.3400
            8   C1x C    17.0997  -17.6400
            9   C1y C    17.0997  -16.2400
            10  C1y C    15.8873  -15.5400
            11  C1y C    18.3122  -15.5400
            12  C1z C    18.3122  -14.1400
            13  C1x C    17.0997  -13.4400
            14  C1x C    15.8873  -14.1400
            15  C1x C    20.7370  -15.5400
            16  C1x C    20.7370  -14.1400
            17  C5x C    19.5246  -13.4400
            18  O5x O    19.5246  -12.0400
            19  O5x O    11.0376  -18.3400
            20  C2a C    15.8873  -19.7400
            21  C1a C    14.6749  -14.8400
            22  C1a C    18.3122  -12.7400
BOND        25
            1     1   2 1
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11    5  10 1
            12    9  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 1
            16   10  14 1
            17   11  15 1
            18   15  16 1
            19   16  17 1
            20   12  17 1
            21   17  18 2
            22    2  19 2
            23    7  20 2
            24    5  21 1 #Up
            25   12  22 1 #Up
///
ENTRY       D01101                      Drug
NAME        Bromperidol (JAN/USAN/INN);
            Impromen (TN)
FORMULA     C21H23BrFNO2
EXACT_MASS  419.0896
MOL_WEIGHT  420.3152
CLASS       Neuropsychiatric agent
             DG01478  Dopamine antagonist
              DG01474  Dopamine D2-receptor antagonist
             DG03200  Antipsychotic agent
              DG01940  Butyrophenone derivative
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 1179
            ATC code: N05AD06
            Chemical structure group: DG00890
            Product (DG00890): D01101<JP>
EFFICACY    Antipsychotic, Dopamine D2 receptor antagonist
COMMENT     Butyrophenone derivative
TARGET      DRD2 [HSA:1813] [KO:K04145]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     CAS: 10457-90-6
            PubChem: 7848164
            ChEBI: 31305
            LigandBox: D01101
            NIKKAJI: J10.460D
ATOM        26
            1   C1b C    19.8100  -17.5700
            2   C1b C    21.0000  -16.8700
            3   C1b C    22.1900  -17.5700
            4   N1y N    23.4500  -16.8700
            5   C1x C    23.4500  -15.4700
            6   C1x C    24.6400  -17.5700
            7   C1x C    24.6400  -14.7700
            8   C1x C    25.8300  -16.8700
            9   C1z C    25.8300  -15.4700
            10  C8y C    27.0200  -14.7700
            11  C8x C    27.0200  -13.4400
            12  C8x C    28.2100  -15.4700
            13  C8x C    28.2100  -12.7400
            14  C8x C    29.4000  -14.7700
            15  C8y C    29.4000  -13.4400
            16  X   Br   30.6600  -12.7400
            17  C5a C    18.5500  -16.8700
            18  C8y C    17.3600  -17.5700
            19  O5a O    18.5500  -15.4000
            20  C8x C    17.3600  -18.9700
            21  C8x C    16.1000  -19.6700
            22  C8y C    14.9100  -18.9700
            23  C8x C    14.9100  -17.5700
            24  C8x C    16.1000  -16.8700
            25  X   F    13.6500  -19.6700
            26  O1a O    27.0424  -16.1700
BOND        28
            1     9  10 1
            2    10  11 1
            3    10  12 2
            4    11  13 2
            5    12  14 1
            6    13  15 1
            7    15  16 1
            8     8   9 1
            9    14  15 2
            10    1  17 1
            11    1   2 1
            12   17  18 1
            13    2   3 1
            14   17  19 2
            15    3   4 1
            16    4   5 1
            17    4   6 1
            18    5   7 1
            19    6   8 1
            20   18  20 1
            21   20  21 2
            22   21  22 1
            23   22  23 2
            24   23  24 1
            25   24  18 2
            26    7   9 1
            27   22  25 1
            28    9  26 1
///
ENTRY       D01553                      Drug
NAME        Manidipine hydrochloride (JP18);
            Manidipine dihydrochloride;
            Calslot (TN)
FORMULA     C35H38N4O6. 2HCl
EXACT_MASS  682.2325
MOL_WEIGHT  683.6213
CLASS       Cardiovascular agent
             DG01928  Dihydropyridine calcium channel blocker
             DG01575  Calcium channel blocker
              DG01496  Calcium channel L type blocker
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2149
            ATC code: C08CA11
            Chemical structure group: DG00324
            Product (DG00324): D01553<JP>
EFFICACY    Antihypertensive, Vasodilator, Calcium channel blocker
COMMENT     Dihydropyridine derivative
TARGET      CACNA1-L [HSA:775 776 778 779] [KO:K04850 K04851 K04853 K04857]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     CAS: 89226-75-5
            PubChem: 7848616
            ChEBI: 31800
            LigandBox: D01553
            NIKKAJI: J321.708F
ATOM        47
            1   C8x C    24.4276  -18.8971
            2   C8x C    24.4276  -17.4973
            3   C8y C    25.6874  -16.7974
            4   C8x C    26.8772  -17.4973
            5   C8y C    26.8772  -18.8971
            6   C8x C    25.6874  -19.5970
            7   C1y C    25.6874  -15.3976
            8   C2y C    24.4276  -14.6978
            9   C2y C    24.4276  -13.2980
            10  N1x N    25.6874  -12.5981
            11  C2y C    26.8772  -13.2980
            12  C2y C    26.8772  -14.6978
            13  C7a C    28.0670  -15.3976
            14  O7a O    29.3268  -14.6978
            15  C1b C    30.5166  -15.3976
            16  C1b C    31.7065  -14.6978
            17  N1y N    32.9662  -15.3976
            18  C1x C    34.1561  -14.6978
            19  C1x C    35.3459  -15.3976
            20  N1y N    35.3459  -16.7974
            21  C1x C    34.1561  -17.4973
            22  C1x C    32.9662  -16.7974
            23  O6a O    28.0670  -16.7974
            24  C1c C    36.6057  -17.4973
            25  C8y C    37.7955  -16.7974
            26  C8y C    36.6057  -18.8971
            27  C8x C    37.7955  -19.5970
            28  C8x C    37.7955  -20.9967
            29  C8x C    36.5357  -21.6966
            30  C8x C    35.3459  -20.9967
            31  C8x C    35.3459  -19.5970
            32  C8x C    37.7955  -15.3976
            33  C8x C    38.9853  -14.6978
            34  C8x C    40.1751  -15.3976
            35  C8x C    40.1751  -16.7974
            36  C8x C    38.9853  -17.4973
            37  C1a C    28.0670  -12.5981
            38  C1a C    23.2378  -12.5981
            39  C7a C    23.2378  -15.3976
            40  O6a O    23.2378  -16.7974
            41  O7a O    22.0480  -14.6978
            42  C1a C    20.7882  -15.3976
            43  N2b N    28.0670  -19.5970 #+
            44  O3a O    29.3268  -18.8971
            45  O3a O    28.0670  -20.9967 #-
            46  X   Cl   43.3945  -17.3573
            47  X   Cl   43.3945  -17.3573
BOND        49
            1    21  22 1
            2    22  17 1
            3     7   8 1
            4    13  23 2
            5     8   9 2
            6    20  24 1
            7     9  10 1
            8    24  25 1
            9    10  11 1
            10   24  26 1
            11   11  12 2
            12   12   7 1
            13    4   5 1
            14   12  13 1
            15    5   6 2
            16   26  27 2
            17   27  28 1
            18   28  29 2
            19   29  30 1
            20   30  31 2
            21   31  26 1
            22   13  14 1
            23    6   1 1
            24   14  15 1
            25   15  16 1
            26   25  32 2
            27   32  33 1
            28   33  34 2
            29   34  35 1
            30   35  36 2
            31   36  25 1
            32    3   7 1
            33   11  37 1
            34   16  17 1
            35    9  38 1
            36    8  39 1
            37   39  40 2
            38    1   2 2
            39   39  41 1
            40    2   3 1
            41   41  42 1
            42    3   4 2
            43    5  43 1
            44   17  18 1
            45   43  44 2
            46   18  19 1
            47   43  45 1
            48   19  20 1
            49   20  21 1
BRACKET     1    41.9300  -18.1300   41.9300  -16.5900
            1    44.1700  -16.5900   44.1700  -18.1300
            1  2
  ORIGINAL  1   46
  REPEAT    1   47
///
ENTRY       D01619                      Drug
NAME        Hydrocortisone butyrate (JP18/USP);
            Locoid (TN)
FORMULA     C25H36O6
EXACT_MASS  432.2512
MOL_WEIGHT  432.5497
CLASS       Anti-inflammatory
             DG01955  Corticosteroid
              DG02068  Glucocorticoid
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 2646
            ATC code: A01AC03 A07EA02 C05AA01 D07AA02 D07AB02 D07XA01 H02AB09 S01BA02 S01CB03 S02BA01
            Chemical structure group: DG00012
            Product (DG00012): D00088<JP/US> D00165<US> D00977<JP> D00978<JP/US> D01619<JP/US> D01886<JP/US> D02288<US>
EFFICACY    Anti-inflammatory, Glucocorticoid receptor agonist
  DISEASE   Atopic dermatitis [DS:H01358]
            Seborrheic dermatitis [DS:H01652]
TARGET      NR3C1 (GR) [HSA:2908] [KO:K05771]
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
DBLINKS     CAS: 13609-67-1
            PubChem: 7848682
            ChEBI: 31674
            LigandBox: D01619
            NIKKAJI: J8.130B
ATOM        31
            1   C1z C    23.4455  -15.4741
            2   C1y C    23.4632  -16.8359
            3   C1z C    24.6253  -14.7814
            4   C1x C    22.2892  -14.7991
            5   C1y C    22.3069  -17.5227
            6   C1x C    25.8286  -16.8824
            7   C1x C    25.8169  -15.4506
            8   C5a C    24.6136  -13.4138
            9   O7a O    25.9754  -14.4939
            10  C1y C    21.0976  -15.4918
            11  C1y C    21.1036  -16.8476
            12  C1x C    22.3069  -18.8845
            13  C1b C    25.8581  -12.7564
            14  O5a O    23.3868  -12.7035
            15  O1a O    19.8767  -14.7874
            16  C1z C    19.9472  -17.5285
            17  C1x C    21.1270  -19.5712
            18  O1a O    27.0672  -13.5018
            19  C2y C    19.9590  -18.8963
            20  C1x C    18.7614  -16.8594
            21  C2x C    18.7732  -19.5889
            22  C1x C    17.5758  -17.5402
            23  C5x C    17.5581  -18.9783
            24  O5x O    16.3665  -19.6182
            25  C7a C    27.1852  -15.1923
            26  C1b C    28.3980  -14.4902
            27  C1b C    29.6109  -15.1923
            28  C1a C    30.8237  -14.4902
            29  O6a O    27.1860  -16.5967
            30  C1a C    23.3905  -14.2074
            31  C1a C    19.9850  -16.2632
BOND        34
            1     3   8 1 #Up
            2     3   9 1 #Down
            3     4  10 1
            4     5  11 1
            5     5  12 1
            6     8  13 1
            7     8  14 2
            8    10  15 1 #Up
            9    11  16 1
            10   12  17 1
            11   13  18 1
            12   16  19 1
            13   16  20 1
            14   19  21 2
            15   20  22 1
            16   21  23 1
            17   23  24 2
            18    6   7 1
            19   10  11 1
            20   17  19 1
            21   22  23 1
            22    9  25 1
            23    1   2 1
            24   25  26 1
            25    1   3 1
            26   26  27 1
            27    1   4 1
            28   27  28 1
            29    2   5 1
            30   25  29 2
            31    2   6 1
            32    1  30 1 #Up
            33    3   7 1
            34   16  31 1 #Up
///
ENTRY       D01624                      Drug
NAME        Sarpogrelate hydrochloride (JP18);
            Anplag (TN)
FORMULA     C24H31NO6. HCl
EXACT_MASS  465.1918
MOL_WEIGHT  465.967
CLASS       Blood modifier agent
             DG01950  Antithrombotic agent
              DG01712  Antiplatelet agent
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG02919  CYP2B6 substrate
             DG01642  CYP2C9 substrate
             DG01639  CYP2C19 substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 3399
            Chemical structure group: DG01333
            Product (DG01333): D01624<JP>
EFFICACY    Anticoagulant, Platelet aggregation inhibitor, Serotonin 5-HT2 receptor antagonist
TARGET      HTR2A [HSA:3356] [KO:K04157]
METABOLISM  Enzyme: CYP1A2 [HSA:1544], CYP2B6 [HSA:1555], CYP2C9 [HSA:1559], CYP2C19 [HSA:1557], CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     CAS: 135159-51-2
            PubChem: 7848687
            ChEBI: 32122
            LigandBox: D01624
            NIKKAJI: J550.747B
ATOM        32
            1   C8y C    20.8521  -17.4758
            2   O2a O    22.0660  -16.7720
            3   C8x C    19.6381  -16.7780
            4   C8y C    20.8521  -18.8773
            5   C1b C    23.2740  -17.4758
            6   C8x C    18.4301  -17.4758
            7   C8x C    19.6441  -19.5753
            8   C1c C    24.4879  -16.7720
            9   C8x C    18.4301  -18.8773
            10  O7a O    25.7019  -17.4758
            11  C1b C    24.4879  -15.3705
            12  C7a C    26.9100  -16.7720
            13  C1b C    28.1240  -17.4758
            14  C1b C    29.3380  -16.7720
            15  C6a C    30.5460  -17.4758
            16  O6a O    31.7599  -16.7720
            17  O6a O    26.9087  -15.3689
            18  O6a O    30.5446  -18.8789
            19  C1b C    22.0614  -19.5687
            20  C1b C    23.2732  -18.8671
            21  C8y C    24.4848  -19.5615
            22  C8x C    24.4893  -20.9581
            23  C8x C    25.7010  -21.6527
            24  C8x C    26.9083  -20.9505
            25  C8y C    26.9039  -19.5539
            26  C8x C    25.6922  -18.8595
            27  O2a O    28.1167  -18.8484
            28  C1a C    29.3341  -19.5460
            29  N1c N    23.2730  -14.6689
            30  C1a C    23.2730  -13.2659
            31  C1a C    22.0579  -15.3705
            32  X   Cl   33.1159  -19.4624
BOND        32
            1    15  16 1
            2     7   9 1
            3    12  17 2
            4    15  18 2
            5     1   2 1
            6     4  19 1
            7     1   3 2
            8    19  20 1
            9     1   4 1
            10   20  21 1
            11    2   5 1
            12    3   6 1
            13    4   7 2
            14    5   8 1
            15    6   9 2
            16   21  22 2
            17   22  23 1
            18   23  24 2
            19   24  25 1
            20   25  26 2
            21   26  21 1
            22    8  10 1
            23   25  27 1
            24    8  11 1
            25   27  28 1
            26   10  12 1
            27   11  29 1
            28   12  13 1
            29   29  30 1
            30   13  14 1
            31   29  31 1
            32   14  15 1
///
ENTRY       D03580                      Drug
NAME        Codeine sulfate (USP);
            Codeine sulfate trihydrate;
            Codeine sulfate (TN)
FORMULA     (C18H21NO3)2. H2SO4. 3H2O
EXACT_MASS  750.3034
MOL_WEIGHT  750.8528
CLASS       Neuropsychiatric agent
             DG01564  Opioid receptor agonist
              DG01563  mu-Opioid receptor agonist
            Analgesic
             DG01984  Opioid analgesics
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
              DG03189  UGT2B4 substrate
              DG03190  UGT2B7 substrate
REMARK      ATC code: R05DA04
            Chemical structure group: DG01076
            Product (DG01076): D02101<JP> D03580<US>
EFFICACY    Analgesic (narcotic), Antitussive, Opioid receptor agonist
COMMENT     Opium alkaloid
            Active form of prodrug: Morphine [DR:D08233]
TARGET      OPRM1 [HSA:4988] [KO:K04215]
METABOLISM  Enzyme: UGT2B7 [HSA:7364], UGT2B4 [HSA:7363]; CYP3A4 [HSA:1576], CYP2D6 [HSA:1565]
INTERACTION  
DBLINKS     CAS: 6854-40-6
            PubChem: 47205864
            LigandBox: D03580
ATOM        52
            1   O0  O    29.9570  -18.1983
            2   C1z C    18.8310  -16.9590
            3   C8y C    18.8310  -15.6336
            4   C1y C    20.0168  -17.6566
            5   C1y C    17.7147  -17.5868
            6   C1x C    20.0168  -16.3312
            7   C8y C    17.7147  -15.0057
            8   C8y C    20.0168  -15.0057
            9   C1y C    21.1330  -16.9590
            10  C2x C    20.0168  -18.9123
            11  O2x O    16.3893  -16.2614
            12  C1y C    17.7147  -18.9123
            13  C1x C    22.2491  -16.3312
            14  C8y C    17.7147  -13.6802
            15  C1x C    21.1330  -15.7033
            16  C8x C    20.0168  -13.6802
            17  N1y N    22.2491  -17.6566
            18  C2x C    18.8310  -19.6099
            19  O1a O    16.5985  -19.6099
            20  C8x C    18.9007  -13.0524
            21  O2a O    16.5985  -13.0524
            22  C1a C    15.4127  -13.6802
            23  C1a C    23.6491  -17.6566
            24  S4a S    28.9520  -14.8100
            25  O1d O    28.9520  -13.4100
            26  O1d O    28.9520  -16.2100
            27  O1d O    27.5519  -14.8100
            28  O1d O    30.3519  -14.8100
            29  O0  O    29.9570  -18.1983
            30  O0  O    29.9570  -18.1983
            31  C1z C    18.8310  -16.9590
            32  C8y C    18.8310  -15.6336
            33  C8y C    17.7147  -15.0057
            34  C8y C    17.7147  -13.6802
            35  C8x C    18.9007  -13.0524
            36  C8x C    20.0168  -13.6802
            37  C8y C    20.0168  -15.0057
            38  C1x C    21.1330  -15.7033
            39  C1y C    21.1330  -16.9590
            40  C1y C    20.0168  -17.6566
            41  C2x C    20.0168  -18.9123
            42  C2x C    18.8310  -19.6099
            43  C1y C    17.7147  -18.9123
            44  C1y C    17.7147  -17.5868
            45  O2x O    16.3893  -16.2614
            46  O1a O    16.5985  -19.6099
            47  N1y N    22.2491  -17.6566
            48  C1x C    22.2491  -16.3312
            49  C1x C    20.0168  -16.3312
            50  C1a C    23.6491  -17.6566
            51  O2a O    16.5985  -13.0524
            52  C1a C    15.4127  -13.6802
BOND        56
            1    24  25 2
            2    24  26 2
            3    24  27 1
            4    24  28 1
            5     2   3 1
            6     2   4 1
            7     2   5 1
            8     2   6 1 #Up
            9     3   7 2
            10    3   8 1
            11    4   9 1
            12    4  10 1
            13    5  11 1 #Down
            14    5  12 1
            15    6  13 1
            16    7  14 1
            17    8  15 1
            18    8  16 2
            19    9  17 1 #Up
            20   10  18 2
            21   12  19 1 #Down
            22   14  20 2
            23   14  21 1
            24   21  22 1
            25    7  11 1
            26    9  15 1
            27   12  18 1
            28   13  17 1
            29   16  20 1
            30   17  23 1
            31   31  32 1
            32   31  40 1
            33   31  44 1
            34   31  49 1 #Up
            35   32  33 2
            36   32  37 1
            37   40  39 1
            38   40  41 1
            39   44  45 1 #Down
            40   44  43 1
            41   49  48 1
            42   33  34 1
            43   37  38 1
            44   37  36 2
            45   39  47 1 #Up
            46   41  42 2
            47   43  46 1 #Down
            48   34  35 2
            49   34  51 1
            50   51  52 1
            51   33  45 1
            52   39  38 1
            53   43  42 1
            54   48  47 1
            55   36  35 1
            56   47  50 1
BRACKET     1    27.7200  -18.9700   27.7200  -17.2900
            1    30.5200  -17.2900   30.5200  -18.9700
            1  3
  ORIGINAL  1    1
  REPEAT    1   30  31
            2    13.4400  -20.3000   13.4400  -12.0400
            2    25.0600  -12.0400   25.0600  -20.3000
            2  2
  ORIGINAL  2    2   3   7  14  20  16   8  15   9   4  10  18  12   5  11  19
            2   23  17  13   6  24  21  22
  REPEAT    2   32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47
            2   48  49  50  51  52  53  54
///
ENTRY       D04461                      Drug
NAME        Hydrocodone polistirex (USAN)
CLASS       Neuropsychiatric agent
             DG01564  Opioid receptor agonist
              DG01563  mu-Opioid receptor agonist
            Metabolizing enzyme substrate
             DG02919  CYP2B6 substrate
             DG01639  CYP2C19 substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: R05DA03
            Chemical structure group: DG01075
            Product (DG01075): D03725<US>
            Product (mixture): D11075<US> D11076<US>
EFFICACY    Antitussive, Opioid receptor agonist
COMMENT     Opium alkaloid
TARGET      OPRM1 [HSA:4988] [KO:K04215]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2D6 [HSA:1565], CYP2B6 [HSA:1555], CYP2C19 [HSA:1557]
INTERACTION  
DBLINKS     PubChem: 47206323
///
ENTRY       D05700                      Drug
NAME        Ranolazine (USAN/INN);
            Ranexa (TN)
FORMULA     C24H33N3O4
EXACT_MASS  427.2471
MOL_WEIGHT  427.5365
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01645  CYP2D6 inhibitor
            Transporter substrate
             DG01665  ABCB1 substrate
REMARK      ATC code: C01EB18
            Chemical structure group: DG00247
            Product (DG00247): D05700<US>
EFFICACY    Vasodilator
  DISEASE   Chronic angina [DS:H01632]
COMMENT     Treatment of chronic angina
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
            Transporter: ABCB1 [HSA:5243]
INTERACTION CYP inhibition: CYP2D6 [HSA:1565]
DBLINKS     CAS: 95635-55-5
            PubChem: 47207361
            ChEBI: 87681
            LigandBox: D05700
            NIKKAJI: J507.863F
ATOM        31
            1   C8y C    22.9497  -20.5107
            2   C8y C    21.7380  -21.2097
            3   O2a O    24.1672  -21.2097
            4   C8x C    22.9497  -19.1126
            5   C8x C    20.5262  -20.5107
            6   O2a O    21.7438  -22.6078
            7   C1b C    25.3730  -20.5107
            8   C8x C    21.7380  -18.4078
            9   C8x C    20.5262  -19.1126
            10  C1a C    20.5262  -23.3185
            11  C1c C    26.5848  -21.2097
            12  C1b C    27.8021  -20.5107
            13  O1a O    26.5848  -22.6078
            14  N1y N    29.0140  -21.2038
            15  C1x C    28.9498  -22.6094
            16  C1x C    30.2351  -23.3044
            17  N1y N    31.4446  -22.5994
            18  C1x C    31.4388  -21.1937
            19  C1x C    30.2235  -20.4988
            20  C1b C    32.6534  -23.2907
            21  C5a C    33.8296  -22.6051
            22  N1b N    35.0321  -23.2930
            23  O5a O    33.8239  -21.2101
            24  C8y C    36.2104  -22.6064
            25  C8y C    37.4117  -23.2938
            26  C8x C    38.6214  -22.5890
            27  C8x C    38.6159  -21.1890
            28  C8x C    37.4146  -20.5017
            29  C8y C    36.2049  -21.2064
            30  C1a C    34.9801  -20.5056
            31  C1a C    37.3476  -24.7095
BOND        33
            1     1   2 2
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     4   8 2
            8     5   9 2
            9     6  10 1
            10    7  11 1
            11   11  12 1
            12   11  13 1
            13   12  14 1
            14    8   9 1
            15   14  15 1
            16   15  16 1
            17   16  17 1
            18   17  18 1
            19   18  19 1
            20   14  19 1
            21   17  20 1
            22   20  21 1
            23   21  22 1
            24   21  23 2
            25   22  24 1
            26   24  25 2
            27   25  26 1
            28   26  27 2
            29   27  28 1
            30   28  29 2
            31   24  29 1
            32   29  30 1
            33   25  31 1
///
ENTRY       D06414                      Drug
NAME        Dasatinib (USAN);
            Dasatinib hydrate (JAN);
            Sprycel (TN)
FORMULA     C22H26ClN7O2S. H2O
EXACT_MASS  505.1663
MOL_WEIGHT  506.0208
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG03161  BCR-ABL inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02950  FMO3 substrate
             DG02924  UGT substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EA02
            Chemical structure group: DG00714
            Product (DG00714): D03658<JP> D06414<JP/US>
EFFICACY    Antineoplastic, Tyrosine kinase inhibitor
  DISEASE   Chronic myeloid leukemia (Philadelphia chromosome positive) [DS:H00004]
            Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS:H00001]
TARGET      BCR-ABL [HSA_VAR:25v2] [HSA:25] [KO:K06619]
            KIT (CD117) [HSA:3815] [KO:K05091]
            SRC [HSA:6714] [KO:K05704]
            LCK [HSA:3932] [KO:K05856]
            YES1 [HSA:7525] [KO:K05705]
            FYN [HSA:2534] [KO:K05703]
            EPHA2 [HSA:1969] [KO:K05103]
            PDGFRB [HSA:5159] [KO:K05089]
  NETWORK   N10002  Second/third-generation tyrosine kinase inhibitor to BCR-ABL fusion
METABOLISM  Enzyme: CYP3A4 [HSA:1576], FMO3 [HSA:2328], UGT [KO:K00699]
INTERACTION  
DBLINKS     CAS: 863127-77-9
            PubChem: 47208070
            ChEBI: 70839
            LigandBox: D06414
ATOM        34
            1   C8y C    13.3022   -5.7416
            2   N5x N    13.3022   -7.1418
            3   C8y C    14.5147   -7.8419
            4   N5x N    15.7274   -7.1418
            5   C8y C    15.7274   -5.7416
            6   C8x C    14.5147   -5.0414
            7   N1b N    12.0896   -5.0414
            8   C8y C    10.8769   -5.7441
            9   S2x S     9.7404   -4.9261
            10  C8y C     8.6113   -5.7541
            11  C8x C     9.0499   -7.0839
            12  N5x N    10.4500   -7.0777
            13  C1a C    14.5147   -9.2418
            14  N1y N    16.9587   -5.0304
            15  C1x C    18.1641   -5.7263
            16  C1x C    19.3766   -5.0260
            17  N1y N    19.3766   -3.6258
            18  C1x C    18.1712   -2.9300
            19  C1x C    16.9586   -3.6302
            20  C1b C    20.5947   -2.9223
            21  C1b C    21.8068   -3.6219
            22  O1a O    22.9858   -2.9409
            23  C5a C     7.4654   -4.9082
            24  N1b N     6.1887   -5.4834
            25  C8y C     5.0522   -4.6655
            26  O5a O     7.4740   -3.5160
            27  C8y C     5.0522   -3.2653
            28  C8x C     3.8396   -2.5652
            29  C8x C     2.6270   -3.2653
            30  C8x C     2.6270   -4.6655
            31  C8y C     3.8396   -5.3656
            32  X   Cl    6.2453   -2.5768
            33  C1a C     3.8394   -6.7900
            34  O0  O    20.3032   -8.7519
BOND        36
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13    8  12 2
            14    3  13 1
            15    5  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   18  19 1
            21   14  19 1
            22   17  20 1
            23   20  21 1
            24   21  22 1
            25   10  23 1
            26   23  24 1
            27   24  25 1
            28   23  26 2
            29   25  27 1
            30   27  28 2
            31   28  29 1
            32   29  30 2
            33   30  31 1
            34   25  31 2
            35   27  32 1
            36   31  33 1
///
ENTRY       D08094                      Drug
NAME        Itopride (INN)
FORMULA     C20H26N2O4
EXACT_MASS  358.1893
MOL_WEIGHT  358.4314
CLASS       Neuropsychiatric agent
             DG01595  Cholinesterase inhibitor
              DG01593  Acetylcholinesterase inhibitor
              DG01594  Butyrylcholinesterase inhibitor
            Gastrointestinal agent
             DG01763  Propulsive
            Metabolizing enzyme substrate
             DG03191  FMO1 substrate
             DG02950  FMO3 substrate
REMARK      ATC code: A03FA07
            Chemical structure group: DG01395
            Product (DG01395): D02729<JP>
EFFICACY    Prokinetic, Dopamine receptor antagonist
COMMENT     Benzamide derivative
TARGET      DRD2 [HSA:1813] [KO:K04145]
            ACHE [HSA:43] [KO:K01049]
METABOLISM  Enzyme: FMO1 [HSA:2326], FMO3 [HSA:2328]
INTERACTION  
DBLINKS     CAS: 122898-67-3
            PubChem: 96024784
            LigandBox: D08094
            NIKKAJI: J354.055C
ATOM        26
            1   C8y C    14.4200  -16.1700
            2   C8x C    14.4200  -14.7700
            3   C8x C    13.1600  -16.8700
            4   C5a C    15.6800  -16.8700
            5   C8x C    13.1600  -14.0700
            6   C8y C    11.9700  -16.1700
            7   N1b N    16.8700  -16.1700
            8   O5a O    15.6800  -18.2700
            9   C8y C    11.9700  -14.7700
            10  O2a O    10.7800  -16.8700
            11  C1b C    18.1300  -16.8700
            12  O2a O    10.7800  -14.0700
            13  C8y C    19.3200  -16.1700
            14  C1a C     9.5200  -14.7700
            15  C1a C     9.5200  -16.2400
            16  C8x C    20.5100  -16.8700
            17  C8x C    21.7000  -16.1700
            18  C8y C    21.7000  -14.7700
            19  C8x C    20.5100  -14.0700
            20  C8x C    19.3200  -14.7700
            21  O2a O    22.9600  -14.0700
            22  C1b C    24.0800  -14.7700
            23  C1b C    25.2700  -14.0700
            24  N1c N    26.5300  -14.7700
            25  C1a C    27.7200  -14.0700
            26  C1a C    26.5300  -16.1700
BOND        27
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 2
            5     3   6 1
            6     4   7 1
            7     4   8 2
            8     5   9 1
            9     6  10 1
            10    7  11 1
            11    9  12 1
            12   11  13 1
            13    6   9 2
            14   12  14 1
            15   10  15 1
            16   13  16 2
            17   16  17 1
            18   17  18 2
            19   18  19 1
            20   19  20 2
            21   13  20 1
            22   18  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   24  25 1
            27   24  26 1
///
ENTRY       D09741            Mixture   Drug
NAME        Drospirenone and ethinylestradiol;
            Drospirenone and ethinylestradiol betadex;
            Angeliq (TN);
            Yaz (TN);
            Flexyess (TN)
COMPONENT   Drospirenone [DR:D03917], (Ethinylestradiol betadex | Ethinyl estradiol [DR:D00554])
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2482
            ATC code: G03FA17
            Product: D09741<JP/US>
EFFICACY    Menstruation disorder agent
COMMENT     Drospirenone is a substrate of CYP3A4.
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     PubChem: 124490481
///
ENTRY       D09796                      Drug
NAME        Hydrocortisone caproate (JAN)
FORMULA     C27H40O6
EXACT_MASS  460.2825
MOL_WEIGHT  460.6029
CLASS       Anti-inflammatory
             DG01955  Corticosteroid
              DG02068  Glucocorticoid
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Same as: C13422
            ATC code: A01AC03 A07EA02 C05AA01 D07AA02 D07XA01 H02AB09 S01BA02 S01CB03 S02BA01
            Chemical structure group: DG00012
            Product (DG00012): D00088<JP/US> D00165<US> D00977<JP> D00978<JP/US> D01619<JP/US> D01886<JP/US> D02288<US>
EFFICACY    Anti-inflammatory, Glucocorticoid receptor agonist
TARGET      NR3C1 (GR) [HSA:2908] [KO:K05771]
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
DBLINKS     CAS: 3593-96-2
            PubChem: 124490536
            ChEBI: 31676
            LigandBox: D09796
ATOM        33
            1   C1z C    29.1900  -22.1200
            2   C1y C    29.1900  -23.4500
            3   C1z C    30.3100  -21.4200
            4   C1x C    28.0000  -21.4200
            5   C1a C    29.1900  -20.7900
            6   C1y C    28.0000  -24.1500
            7   C1x C    31.5000  -23.4500
            8   C1x C    31.5000  -22.1200
            9   C5a C    30.3100  -20.0900
            10  C1y C    26.8100  -22.1200
            11  C1y C    26.8100  -23.4500
            12  C1x C    28.0000  -25.4800
            13  C1b C    31.5000  -19.3900
            14  O5a O    29.0500  -19.3900
            15  O1a O    25.6200  -21.4200
            16  C1z C    25.6900  -24.1500
            17  C1x C    26.8100  -26.1800
            18  O7a O    32.7600  -20.1600
            19  C2y C    25.6900  -25.4800
            20  C1x C    24.5000  -23.5200
            21  C7a C    33.9500  -19.4600
            22  C2x C    24.5000  -26.1800
            23  C1x C    23.3100  -24.1500
            24  C1b C    35.1400  -20.1600
            25  O6a O    33.9500  -18.0600
            26  C5x C    23.3100  -25.6200
            27  C1b C    36.3300  -19.4600
            28  C1b C    37.5200  -20.1600
            29  O5x O    22.1200  -26.3200
            30  C1a C    25.6900  -22.7500
            31  C1b C    38.7100  -19.4600
            32  C1a C    39.9700  -20.1600
            33  O1a O    31.5924  -21.0700
BOND        36
            1     2   6 1
            2     2   7 1
            3     3   8 1
            4     3   9 1 #Up
            5     4  10 1
            6     6  11 1
            7     6  12 1
            8     9  13 1
            9     9  14 2
            10   10  15 1 #Up
            11   11  16 1
            12   12  17 1
            13   13  18 1
            14   16  19 1
            15   16  20 1
            16   18  21 1
            17   19  22 2
            18   20  23 1
            19   21  24 1
            20   21  25 2
            21   22  26 1
            22   24  27 1
            23   27  28 1
            24    7   8 1
            25   10  11 1
            26   17  19 1
            27   23  26 1
            28   26  29 2
            29    1   2 1
            30   16  30 1 #Up
            31    1   3 1
            32   28  31 1
            33    1   4 1
            34   31  32 1
            35    1   5 1 #Up
            36    3  33 1 #Down
///
ENTRY       D09959                      Drug
NAME        Ruxolitinib (USAN/INN)
FORMULA     C17H18N6
EXACT_MASS  306.1593
MOL_WEIGHT  306.365
CLASS       Immunological agent
             DG02020  JAK inhibitor
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: L01EJ01
            Chemical structure group: DG00719
            Product (DG00719): D09960<JP/US>
EFFICACY    Antineoplastic, Janus kinase (JAK) inhibitor
TARGET      JAK1 [HSA:3716] [KO:K11217]
            JAK2 [HSA:3717] [KO:K04447]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2C9 [HSA:1559]
INTERACTION  
DBLINKS     CAS: 941678-49-5
            PubChem: 135626684
            ChEBI: 66919
            PDB-CCD: RXT
            LigandBox: D09959
ATOM        23
            1   C8x C    19.8100  -17.0100
            2   N5x N    19.8100  -18.4100
            3   C8y C    21.0000  -19.1100
            4   C8y C    22.2600  -18.4100
            5   C8y C    22.2600  -17.0100
            6   N5x N    21.0000  -16.3100
            7   C8x C    23.5900  -18.8300
            8   C8x C    24.3600  -17.7100
            9   N4x N    23.5900  -16.5900
            10  C8y C    21.0000  -20.5100
            11  C8x C    19.8800  -21.3500
            12  N4y N    20.3000  -22.6800
            13  N5x N    21.7000  -22.6800
            14  C8x C    22.1900  -21.3500
            15  C1b C    17.9200  -22.6800
            16  C1c C    19.1100  -23.3800
            17  C1y C    19.1100  -24.7800
            18  C3b C    17.9314  -21.2800
            19  N3a N    17.9314  -19.8800
            20  C1x C    17.9774  -25.6029
            21  C1x C    18.4100  -26.9344
            22  C1x C    19.8100  -26.9344
            23  C1x C    20.2426  -25.6029
BOND        26
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    5   9 1
            11    3  10 1
            12   10  11 2
            13   11  12 1
            14   12  13 1
            15   13  14 2
            16   10  14 1
            17   15  16 1
            18   16  12 1
            19   16  17 1 #Up
            20   15  18 1
            21   18  19 3
            22   17  20 1
            23   20  21 1
            24   21  22 1
            25   22  23 1
            26   17  23 1
///
ENTRY       D10191                      Drug
NAME        Safinamide mesylate (USAN);
            Safinamide mesilate (JAN);
            Safinamide methanesulfonate;
            Xadago (TN);
            Equfina (TN)
FORMULA     C17H19FN2O2. CH4SO3
EXACT_MASS  398.1312
MOL_WEIGHT  398.449
CLASS       Neuropsychiatric agent
             DG01568  MAO inhibitor
              DG01512  Monoamine oxidase B inhibitor
             DG01967  Antiparkinson agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02917  MAO substrate
              DG03178  MAOA substrate
REMARK      Therapeutic category: 1169
            ATC code: N04BD03
            Chemical structure group: DG01260
            Product (DG01260): D10191<JP/US>
EFFICACY    Antiparkinsonian, Monoamine oxidase B (MAO-B) inhibitor
  DISEASE   Parkinson's disease [DS:H00057]
COMMENT     Treatment of Parkinson's disease
TARGET      MAOB [HSA:4129] [KO:K00274]
METABOLISM  Enzyme: MAOA [HSA:4128]; CYP3A4 [HSA:1576]
INTERACTION  
DBLINKS     CAS: 202825-46-5
            PubChem: 135626909
            LigandBox: D10191
ATOM        27
            1   C8x C     6.0200  -24.5000
            2   C8x C     6.0200  -23.1000
            3   C8x C     7.2100  -22.4000
            4   C8y C     8.4700  -23.1000
            5   C8x C     8.4700  -24.5000
            6   C8y C     7.2100  -25.2000
            7   C1b C     9.6600  -22.4000
            8   O2a O    10.8500  -23.1000
            9   C8y C    12.0400  -22.4000
            10  C8x C    12.0400  -21.0000
            11  C8x C    13.3700  -20.3000
            12  C8y C    14.5600  -21.0000
            13  C8x C    14.5600  -22.4000
            14  C8x C    13.3700  -23.1000
            15  C1b C    15.7500  -20.3000
            16  N1b N    16.9400  -21.0000
            17  C1c C    18.1300  -20.3000
            18  C5a C    19.3200  -21.0000
            19  N1a N    20.5100  -20.3000
            20  O5a O    19.3200  -22.4000
            21  C1a C    18.1300  -18.9000
            22  X   F     7.2100  -26.6000
            23  S4a S    21.9800  -25.1300
            24  O1d O    21.9800  -23.7300
            25  O1d O    21.9800  -26.5300
            26  C1a C    20.5800  -25.1300
            27  O1d O    23.3800  -25.1300
BOND        27
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15    9  14 1
            16   12  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   18  19 1
            21   18  20 2
            22   17  21 1 #Up
            23    6  22 1
            24   23  24 2
            25   23  25 2
            26   23  26 1
            27   23  27 1
///
ENTRY       D10675                      Drug
NAME        Valbenazine (USAN/INN)
FORMULA     C24H38N2O4
EXACT_MASS  418.2832
MOL_WEIGHT  418.5695
CLASS       Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
REMARK      ATC code: N07XX13
            Chemical structure group: DG02115
            Product (DG02115): D10999<JP/US>
EFFICACY    Neuroleptic, Vesicular monoamine transporter inhibitor
COMMENT     Treatment of hyperkinetic movement disorders
TARGET      SLC18A2 (VMAT2) [HSA:6571] [KO:K08155]
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]; CYP2D6 [HSA:1565]
INTERACTION  
DBLINKS     CAS: 1025504-45-3
            PubChem: 254741636
ATOM        30
            1   C8y C    14.9800  -18.2700
            2   C8y C    14.9800  -19.6700
            3   C8x C    16.1924  -20.3700
            4   C8y C    17.4049  -19.6700
            5   C8y C    17.4049  -18.2700
            6   C8x C    16.1924  -17.5700
            7   O2a O    13.7676  -17.5700
            8   C1a C    12.5551  -18.2700
            9   C1a C    12.5551  -19.6700
            10  O2a O    13.7676  -20.3700
            11  C1x C    18.6173  -20.3700
            12  C1x C    19.8297  -19.6700
            13  N1y N    19.8297  -18.2700
            14  C1y C    18.6173  -17.5700
            15  C1x C    21.0422  -17.5700
            16  C1y C    21.0422  -16.1700
            17  C1y C    19.8297  -15.4700
            18  C1x C    18.6173  -16.1700
            19  C1a C    23.4670  -17.5700
            20  C1c C    23.4670  -16.1700
            21  C1b C    22.2546  -15.4700
            22  O7a O    19.8297  -14.0700
            23  C7a C    18.6173  -13.3700
            24  C1c C    17.4049  -14.0700
            25  N1a N    17.4049  -15.4700
            26  C1c C    16.1925  -13.3700
            27  C1a C    14.9800  -14.0700
            28  C1a C    16.1925  -11.9700
            29  C1a C    24.6794  -15.4700
            30  O6a O    18.6173  -11.9700
BOND        32
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 1
            9     9  10 1
            10    2  10 1
            11    4  11 1
            12   11  12 1
            13   12  13 1
            14   13  14 1
            15    5  14 1
            16   13  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   14  18 1
            21   19  20 1
            22   20  21 1
            23   16  21 1 #Down
            24   22  23 1
            25   23  24 1
            26   17  22 1 #Up
            27   24  25 1 #Up
            28   24  26 1
            29   26  27 1
            30   26  28 1
            31   20  29 1
            32   23  30 2
///
ENTRY       D10766                      Drug
NAME        Osimertinib mesylate (USAN);
            Osimertinib mesilate (JAN);
            Tagrisso (TN)
FORMULA     C28H33N7O2. CH4SO3
EXACT_MASS  595.2577
MOL_WEIGHT  595.713
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Transporter inhibitor
             DG02862  ABCG2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01EB04
            Product: D10766<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Non-small cell lung cancer (EGFR mutation positive) [DS:H00014]
TARGET      EGFR* [HSA_VAR:1956v3] [HSA:1956] [KO:K04361]
  NETWORK   N10006  Third-generation tyrosine kinase inhibitor to EGFR mutation
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION Transporter inhibition: ABCG2 [HSA:9429]
DBLINKS     CAS: 1421373-66-1
            PubChem: 310920484
            ChEBI: 90948
ATOM        42
            1   C8y C    15.8155  -13.2242
            2   N5x N    15.8155  -14.6236
            3   C8y C    17.0050  -15.3233
            4   N5x N    18.2645  -14.6236
            5   C8x C    18.2645  -13.2242
            6   C8x C    17.0050  -12.5245
            7   C8y C    14.6003  -12.5262
            8   C8x C    14.6279  -11.1251
            9   N4y N    13.3039  -10.6659
            10  C8y C    12.4581  -11.7832
            11  C8y C    13.2592  -12.9328
            12  C8x C    11.0637  -11.9021
            13  C8x C    10.4694  -13.1690
            14  C8x C    11.2707  -14.3187
            15  C8x C    12.6650  -14.1998
            16  C1a C    12.8886   -9.2966
            17  N1b N    16.9878  -16.7226
            18  C8y C    18.2037  -17.4448
            19  C8x C    18.1866  -18.8219
            20  C8y C    19.3897  -19.5366
            21  C8y C    20.6803  -18.8521
            22  C8x C    20.6274  -17.4750
            23  C8y C    19.4243  -16.7602
            24  O2a O    19.3720  -15.3934
            25  C1a C    20.6720  -14.7043
            26  N1b N    19.3724  -20.9210
            27  C5a C    18.1606  -21.6005
            28  C2b C    16.9914  -20.9059
            29  O5a O    18.1425  -23.0191
            30  C2a C    15.7749  -21.5882
            31  N1c N    21.8239  -19.5735
            32  C1b C    23.0438  -18.8898
            33  C1a C    21.8058  -20.9907
            34  C1b C    24.2317  -19.5961
            35  N1c N    25.4394  -18.9193
            36  C1a C    26.6533  -19.6413
            37  C1a C    25.3871  -17.4925
            38  S4a S    25.1915  -11.9653
            39  O1d O    25.1915  -10.5658
            40  O1d O    25.1915  -13.3647
            41  C1a C    23.7921  -11.9653
            42  O1d O    26.5909  -11.9653
BOND        44
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12    7  11 1
            13   10  12 2
            14   12  13 1
            15   13  14 2
            16   14  15 1
            17   11  15 2
            18    9  16 1
            19    3  17 1
            20   17  18 1
            21   18  19 2
            22   19  20 1
            23   20  21 2
            24   21  22 1
            25   22  23 2
            26   18  23 1
            27   23  24 1
            28   24  25 1
            29   20  26 1
            30   26  27 1
            31   27  28 1
            32   27  29 2
            33   28  30 2
            34   21  31 1
            35   31  32 1
            36   31  33 1
            37   32  34 1
            38   34  35 1
            39   35  36 1
            40   35  37 1
            41   38  39 2
            42   38  40 2
            43   38  41 1
            44   38  42 1
///
ENTRY       D11472                      Drug
NAME        Remdesivir (JAN/USAN);
            Veklury (TN)
FORMULA     C27H35N6O8P
EXACT_MASS  602.2254
MOL_WEIGHT  602.576
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
             DG02970  CES substrate
            Transporter substrate
             DG03001  CTSA substrate
REMARK      Therapeutic category: 6250
            ATC code: J05AB16
            Product: D11472<JP/US>
EFFICACY    Antiviral, RNA polymerase inhibitor
  DISEASE   Coronavirus disease 2019 [DS:H02398]
COMMENT     Active form of prodrug: GS-441524 [CPD:C22275]
            nucleoside analog
            Treatment of viral infections (broad-spectrum)
TARGET      SARS coronavirus replicase [KO:K24149]
METABOLISM  Enzyme: CES [HSA:1066 8824 23491 221223]; CTSA [HSA:5476], CYP3A [HSA:1576 1577 1551]
INTERACTION  
DBLINKS     CAS: 1809249-37-3
            PubChem: 384585448
            ChEBI: 145994
ATOM        42
            1   C8y C    29.6800  -15.4000
            2   N4y N    31.0800  -14.9800
            3   C1z C    28.3500  -15.8200
            4   C8x C    28.9100  -14.2100
            5   C8y C    31.0800  -13.5800
            6   N5x N    32.3400  -15.7500
            7   O2x O    27.1600  -14.9800
            8   C1y C    27.8600  -17.2200
            9   C8x C    29.7500  -13.0900
            10  C8y C    32.3400  -12.9500
            11  C8x C    33.5300  -15.1200
            12  C1y C    26.0400  -15.8200
            13  C1y C    26.4600  -17.2200
            14  O1a O    28.7700  -18.3400
            15  N5x N    33.5300  -13.7200
            16  N1a N    32.3400  -11.5500
            17  O1a O    25.6900  -18.3400
            18  C3b C    29.5400  -16.5200
            19  N3a N    30.8000  -17.2200
            20  C1b C    24.8500  -15.1200
            21  O2b O    23.6600  -15.8200
            22  P1b P    22.4419  -15.1299
            23  N1b N    21.2295  -15.8299
            24  C1c C    19.9982  -15.1190
            25  C7a C    18.8018  -15.8099
            26  O2b O    22.4360  -13.7204
            27  O3b O    23.6544  -14.4299
            28  C8y C    23.6709  -13.0003
            29  C8x C    24.8864  -13.6952
            30  C8x C    26.0958  -12.9899
            31  C8x C    26.0898  -11.5899
            32  C8x C    24.8742  -10.8951
            33  C8x C    23.6648  -11.6003
            34  C1a C    19.9981  -13.7202
            35  O7a O    17.6149  -15.1246
            36  O6a O    18.8016  -17.2197
            37  C1b C    16.4234  -15.8127
            38  C1c C    15.2341  -15.1261
            39  C1b C    14.0438  -15.8135
            40  C1b C    15.2338  -13.7202
            41  C1a C    14.0410  -13.0315
            42  C1a C    12.8538  -15.1265
BOND        45
            1     1   2 1
            2     3   1 1 #Up
            3     1   4 2
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     3   8 1
            8     4   9 1
            9     5  10 1
            10    6  11 2
            11    7  12 1
            12    8  13 1
            13    8  14 1 #Down
            14   10  15 2
            15   10  16 1
            16   13  17 1 #Down
            17    5   9 2
            18   11  15 1
            19   12  13 1
            20    3  18 1 #Down
            21   18  19 3
            22   20  21 1
            23   12  20 1 #Up
            24   21  22 1
            25   22  23 1 #Down
            26   23  24 1
            27   24  25 1
            28   22  26 1 #Up
            29   22  27 2
            30   26  28 1
            31   28  29 2
            32   29  30 1
            33   30  31 2
            34   31  32 1
            35   32  33 2
            36   28  33 1
            37   24  34 1 #Down
            38   25  35 1
            39   25  36 2
            40   35  37 1
            41   37  38 1
            42   38  39 1
            43   38  40 1
            44   40  41 1
            45   39  42 1
///
ENTRY       D11700            Mixture   Drug
NAME        Elexacaftor, ivacaftor and tezacaftor;
            Trikafta (TN);
            Kaftrio (TN)
COMPONENT   Elexacaftor [DR:D11507], Ivacaftor [DR:D09916], Tezacaftor [DR:D11041]
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      ATC code: R07AX32
            Product: D11700<US>
EFFICACY    Cystic fibrosis treatment
  DISEASE   Cystic fibrosis (CFTR F508del mutation) [DS:H00218]
TARGET      CFTR* [HSA_VAR:1080v1] [HSA:1080] [KO:K05031]
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
DBLINKS     PubChem: 405226566
///
